Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

Studies in patients with type 2 diabetes are needed to further assess and allow comparison of several GLP-1RA agents' impact on steady-state pharmacokinetics and pharmacodynamics of concomitant ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

"We think there will be a material pick up this year." Pot also discusses challenges in the GLP-1 market but cites innovation in drug delivery. To watch more expert insights and analysis on the latest ...

Earlier this month, the FDA put out a statement saying that it, too, was concerned about patients and healthcare professionals turning to unapproved versions of GLP-1 drugs as an option for weight ...

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years ...